Information Provided By: 
Fly News Breaks for November 13, 2017
FPRX
Nov 13, 2017 | 05:45 EDT
Nomura Instinet analyst Christopher Marai believes the cabira+nivo data has been taken out of context and that the recent selloff in shares of Five Prime Therapeutics looks unfounded. The data highlight "remarkable durable responses in patients not expected to respond," Marai tells investors in a research note. He points out that the IDO inhibitor epacadostat routinely only results in 10% benefit in overall response rate. Marai keeps a Buy rating on Five Prime with a $94 price target.
News For FPRX From the Last 2 Days
There are no results for your query FPRX
